MicroSeal Hip System Problems Result in Warning Letter to Signal

Signal Medical Corp. has received a warning letter from federal regulators about a failure to obtain required premarket approvals for a hip replacement system before placing the product on the market, potentially exposing consumers to a risk of injury from unknown and untested device hazards. 

Earlier this month the FDA released a letter sent to Signal Medical Corp. after discovering the company began selling MicroSeal Total Hip Acetabular Systems with significant changes to the device without the proper FDA approval.

The MicroSeal Total Hip Acetabular Systems are non-cemented total hip replacement devices that are implanted by physicians in those with failing hips. The devices are sold in various sizes to accommodate the patient’s bone structure.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

On July 31, 2014, the FDA began inspecting the firm’s Michigan plant, where investigators identified multiple regulatory violations. The investigators discovered that Signal had made significant changes to the device, including the addition of a hood liner, adding new sizes of the device, changing the shell design, and modifying the liner without clearing the changes with the FDA before introducing it to the market for distribution and sale.

The FDA’s report indicates that Signal did not add these changes and additional sizes of the device in their prior premarket approval application. Failure to submit a premarket notification for device modifications to the FDA is a direct violation under the Federal Food, Drug, and Cosmetic Act (the Act) 21 U.S.C. and the company could face penalties if not handled within the appropriate timeframe and manner required under the laws.

In the FDA’s warning letter to Signal Medical Corp., the company was given 15 days to respond to the violations with steps the firm has taken to correct the noted violations as well as an explanation of how the company plans to prevent similar future occurrences. The FDA notes in the warning that if the company fails to comply with these demands that regulatory action could be taken without further notice to include seizures, injunctions, and civil money penalties as well as public warning letters about the devices so that the federal agencies take the information into account when considering the award of contracts.


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

AT&T Data Breach Class Action Claims Telecom Giant
AT&T Data Breach Class Action Claims Telecom Giant "Disregarded" Customer Financial Safety (Posted today)

A Missouri woman is one of the latest person to file an class action claim over the AT&T data breach, after the telecom company admitted that hackers stole millions of customers' personal information and sold it on the internet.

Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL
Plaintiffs Oppose Phased Discovery Over Suboxone Tooth Decay Risks in MDL (Posted yesterday)

Plaintiffs say a federal judge should not waste time on a phased discovery plan requiring them to first prove Suboxone strips can cause tooth decay, saying the science is obvious and such a plan could delay resolution of hundreds of product liability lawsuits.